← Research library

Dilept versus risperidone in a 28-day psychiatric comparison

Comparison in people · 2021

What was studied
25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
Main finding
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.

Reported findings and study design

Active-comparator study using the PANSS negative-symptom subscale, grouped psychiatric symptoms and WAIS-R testing.

Population or model 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.

Dose, route and schedule

Dilept 200 mg/day or risperidone 2 mg/day for 28 days. Phenazepam up to 2 mg was permitted as needed during days 1–14. From day 15, the report describes combinations with 0.5–2 mg of phenazepam.

Protocol source ↗ · Original journal abstract and comparison with the group’s 2017 and 2020 reports.

Results · Original journal abstract and comparison with the group’s 2017 and 2020 reports.
MeasureResultComparison, timing and statistics
WAIS-R digit-symbol codingReported difference in change −1.90 points, favoring Dilept under the authors’ sign conventionDay 28 · Reported interval −3.43 to −0.36
PANSS negative symptoms and grouped psychiatric symptomsNo statistically significant between-group differences in reported changesDay 28

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • Small comparison with symptom and cognitive endpoints. Benzodiazepine use complicates attribution. The paper may reuse the 15-person, 200 mg/day arm of the earlier Zakusov pilot.

Related publications may describe some of the same participants or experiments.

Source details

Original journal abstract and comparison with the group’s 2017 and 2020 reports.

Sources checked

Citation

Human comparative studyEnglish abstract

I. O. Bogdanova, T. S. Syunyakov, G. G. Neznamov, A. A. Chepelyuk, T. V. Kovalenok, O. A. Dorofeeva. Dilept versus risperidone in a 28-day psychiatric comparison Experimental and Clinical Pharmacology. 2021;84(8):3–12.

Study source ↗ · DOI 10.30906/0869-2092-2021-84-8-3-12 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards